Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer

CDK4/6 inhibitors represent a new treatment standard for hormone receptor-positive (HR+), HER2-negative advanced breast cancer (BC) patients. Although efficacious, resistance to these agents is universal. Here, we profiled a large panel of HR+ BC cell lines with conditioned resistance to the CDK4/6...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:NPJ Breast Cancer
Autori principali: Guarducci, Cristina, Bonechi, Martina, Benelli, Matteo, Biagioni, Chiara, Boccalini, Giulia, Romagnoli, Dario, Verardo, Roberto, Schiff, Rachel, Osborne, C. Kent, De Angelis, Carmine, Di Leo, Angelo, Malorni, Luca, Migliaccio, Ilenia
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6261939/
https://ncbi.nlm.nih.gov/pubmed/30511015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0092-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi